Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaun Chou

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
JAMA Dermatology|July 23, 2015
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic MelanomaGiuliana Carlos, Rachael Anforth, Arthur Clements, et al.
Pathology|November 21, 2020
Duodenal plasma cells correspond to serum IgA in common variable immunodeficiencyJonathan Emerson, David K van der Poorten, Ming Wei Lin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 26, 2018
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic MelanomaCathy Yunjia Zhao, Shelley Ji Eun Hwang, Rachael Anforth, et al.
Journal of the American Academy of Dermatology|June 25, 2019
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse eventsLinda Chan, Shelley J E Hwang, Karen Byth, et al.
The Australasian Journal of Dermatology|December 7, 2021
Merkel cell carcinoma in situ: A systematic review of prognosis and managementKelvin Truong, Simone M Goldinger, Shaun Chou, et al.
Journal of the American Academy of Dermatology|March 10, 2015
Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapyRachael Anforth, Alexander Menzies, Karen Byth, et al.
Journal of the American Academy of Dermatology|January 23, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortShelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
The Lancet. Oncology|December 25, 2025
International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiativeRuta Gupta, Timothy Fielder, Munita Bal, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
JAMA Dermatology|July 23, 2015
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic MelanomaGiuliana Carlos, Rachael Anforth, Arthur Clements, et al.
Pathology|November 21, 2020
Duodenal plasma cells correspond to serum IgA in common variable immunodeficiencyJonathan Emerson, David K van der Poorten, Ming Wei Lin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 26, 2018
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic MelanomaCathy Yunjia Zhao, Shelley Ji Eun Hwang, Rachael Anforth, et al.
Journal of the American Academy of Dermatology|June 25, 2019
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse eventsLinda Chan, Shelley J E Hwang, Karen Byth, et al.
The Australasian Journal of Dermatology|December 7, 2021
Merkel cell carcinoma in situ: A systematic review of prognosis and managementKelvin Truong, Simone M Goldinger, Shaun Chou, et al.
Journal of the American Academy of Dermatology|March 10, 2015
Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapyRachael Anforth, Alexander Menzies, Karen Byth, et al.
Journal of the American Academy of Dermatology|January 23, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortShelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
The Lancet. Oncology|December 25, 2025
International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiativeRuta Gupta, Timothy Fielder, Munita Bal, et al.
Pageof 3